Enzolytics Inc (ENZC)

[falon]

Happy Holidays to All

What a way for ENZC to end the year with such GREAT NEWS. Dot the i and cross the t have been ENZC philosophy.

Are we there yet?

No, however the train has left the station.

It has been over 2 years of blood, sweat and tears. Rumors, speculations and and many close encounters with legit players, ENZC never loss focus of the task at hand.

While HIV has always been the central focus, the work along the way has opened up unlimited potential for ENZC.

There is favorable profit potential for the HIV therapy and definitely entities that don't what ENZC products in the markets as it will cut into their profits. It will be very very interesting how this plays out in the weeks and months ahead.

Technology Potential

Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm.
This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North America and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. The potential earnings and underlying assumptions for application of our passive immunotherapy to major Markets are set forth here:

Potential Profit from Technology

A most appropriate market for the Company’s therapy includes the regions referred to as the “Major Markets”, including North American, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America wherein there are 10.6 million HIV positive individuals. Assuming a penetration rate of 1% rising to a maximum 15% over a five-year period, profit from making treatment available to these 10.6 million HIV positive individuals in the 7 major world markets would be $105 billion in the first 11 years.

Patient Population:

Major Markets – HIV population[1]

North America, Western and Central Europe - 2.2 million

Eastern Europe and Central Asia – 1.4 million

South and Southeast Asia (including India) – 5.2 million

Latin America – 1.8 million

Total – 10.6 million

Assumes 10.6 million potential patient populations with HIV/AIDS

Assumes 1.5% annual increase in potential population growth over the forecast period

$8,000 treatment total cost per patient (single series of treatments for one year only)

(Without insurance coverage, the average monthly cost of Biktarvy (30, 50-200-25 mg tablets) is $7,797, or a little over $90,000 for one year of treatment. The actual cash price of the drug will depend on the quantity and dosage prescribed by a healthcare provider, as well as the location where the drug is purchased.) https://www.singlecare.com/blog/biktarvy-without insurance/#:~:text=Without%20insurance%20coverage%2C%20the%20average,for%20one%20year%20of%20treatment.



Assumes penetration of from 1% in year one to maximum of 15%

An HIV vaccine.

A vaccine against HIV has a much broader application and will produce significantly larger earnings


https://www.bloomberg.com/press-releases/2022-04-25/enzolytics-inc-reports-progress-and-future-plans